These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 26694174)
1. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. Yang MC; Lin RW; Huang SB; Huang SY; Chen WJ; Wang S; Hong YR; Wang C Cell Cycle; 2016; 15(3):394-402. PubMed ID: 26694174 [TBL] [Abstract][Full Text] [Related]
2. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells. Wang C; Huang SB; Yang MC; Lin YT; Chu IH; Shen YN; Chiu YH; Hung SH; Kang L; Hong YR; Chen CH PLoS One; 2015; 10(3):e0120913. PubMed ID: 25811469 [TBL] [Abstract][Full Text] [Related]
3. P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage. Lin RW; Ho CJ; Chen HW; Pao YH; Chen LE; Yang MC; Huang SB; Wang S; Chen CH; Wang C Cell Cycle; 2018; 17(17):2175-2186. PubMed ID: 30198376 [TBL] [Abstract][Full Text] [Related]
4. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53. Zhang J; Huang K; O'Neill KL; Pang X; Luo X Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874 [TBL] [Abstract][Full Text] [Related]
5. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Rooswinkel RW; van de Kooij B; Verheij M; Borst J Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003 [TBL] [Abstract][Full Text] [Related]
6. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126 [TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017 [TBL] [Abstract][Full Text] [Related]
9. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320 [TBL] [Abstract][Full Text] [Related]
10. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266 [TBL] [Abstract][Full Text] [Related]
11. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. Hastak K; Agarwal MK; Mukhtar H; Agarwal ML FASEB J; 2005 May; 19(7):789-91. PubMed ID: 15764647 [TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Eichhorn JM; Alford SE; Sakurikar N; Chambers TC Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425 [TBL] [Abstract][Full Text] [Related]
13. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells. Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436 [TBL] [Abstract][Full Text] [Related]
14. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer. Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046 [TBL] [Abstract][Full Text] [Related]
15. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028 [TBL] [Abstract][Full Text] [Related]
16. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Follis AV; Chipuk JE; Fisher JC; Yun MK; Grace CR; Nourse A; Baran K; Ou L; Min L; White SW; Green DR; Kriwacki RW Nat Chem Biol; 2013 Mar; 9(3):163-8. PubMed ID: 23340338 [TBL] [Abstract][Full Text] [Related]
17. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Lim DY; Park JH Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1060-8. PubMed ID: 19264955 [TBL] [Abstract][Full Text] [Related]
18. Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Ohno I; Eibl G; Odinokova I; Edderkaoui M; Damoiseaux RD; Yazbec M; Abrol R; Goddard WA; Yokosuka O; Pandol SJ; Gukovskaya AS Am J Physiol Gastrointest Liver Physiol; 2010 Jan; 298(1):G63-73. PubMed ID: 19762431 [TBL] [Abstract][Full Text] [Related]
19. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100 [TBL] [Abstract][Full Text] [Related]
20. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]